Summary
Vertex Pharmaceuticals Inc. reported strong financial performance in its 2022 10-K filing, driven by continued growth in its cystic fibrosis (CF) franchise, particularly the TRIKAFTA/KAFTRIO regimen. Net product revenues increased by 18% to $8.9 billion, primarily attributed to the international expansion of TRIKAFTA/KAFTRIO and its approval for younger pediatric patients. The company's robust pipeline continues to advance across multiple therapeutic areas, including sickle cell disease, beta thalassemia, pain, APOL1-mediated kidney disease, and type 1 diabetes. Significant progress was made with exagamglogene autotemcel (exa-cel) for sickle cell disease and beta thalassemia, with regulatory submissions completed in Europe and ongoing rolling submission in the U.S. Vertex ended 2022 with a strong cash position of $10.8 billion, providing ample resources for ongoing research and development, strategic acquisitions, and potential share repurchases. The company's focus remains on scientific innovation to develop transformative medicines for serious diseases.
Financial Highlights
50 data points| Revenue | $8.93B |
| Cost of Revenue | $1.08B |
| Gross Profit | $7.85B |
| SG&A Expenses | $944.70M |
| Operating Expenses | $4.62B |
| Operating Income | $4.31B |
| Net Income | $3.32B |
| EPS (Basic) | $12.97 |
| EPS (Diluted) | $12.82 |
| Shares Outstanding (Basic) | 256.10M |
| Shares Outstanding (Diluted) | 259.10M |
Key Highlights
- 1Net product revenues grew 18% to $8.9 billion in 2022, largely driven by the strong performance and international expansion of TRIKAFTA/KAFTRIO for cystic fibrosis.
- 2The company made significant progress in its non-CF pipeline, notably completing European regulatory submissions for exa-cel (gene-editing therapy) for sickle cell disease and beta thalassemia.
- 3Vertex initiated three Phase 3 clinical trials for vanzacaftor/tezacaftor/deutivacaftor, a potential new once-daily triple combination therapy for CF.
- 4The company is developing VX-522, an mRNA therapeutic for CF patients who do not benefit from CFTR modulators, with an IND cleared by the FDA and a clinical trial initiated.
- 5Development is advancing for VX-548, a non-opioid NaV1.8 inhibitor for pain, with positive Phase 2 data and initiation of Phase 3 trials.
- 6Vertex maintains a strong financial position with $10.8 billion in cash, cash equivalents, and marketable securities as of December 31, 2022.
- 7The company announced a new $3.0 billion share repurchase program in February 2023, demonstrating confidence in its financial future and commitment to shareholder returns.